INTRODUCTION: Atrial fibrillation (AF) can cause or aggravate heart failure (HF). Catheter ablation (CA) is an effective treatment for AF. This study focused on the feasibility and outcomes of emergent AF ablation performed during hospitalization for acute HF. METHODS AND RESULTS: We retrospectively investigated patients who underwent emergent CA for AF during hospitalization for acute HF in 2018-2024. Arrhythmia recurrence was the primary endpoint. The combination of arrhythmia recurrence, HF hospitalization, and all-cause death was the secondary endpoint. Patients were censored 1 year after the index procedure. We included 46 patients, 35% females, with median age of 67 [interquartile rage: 61, 72] years and left ventricular ejection fraction (LVEF) of 25 [23, 28]%. Thermal CA was performed in 14 patients, and pulsed field ablation (PFA) in 32 patients. Procedure time was significantly shorter with PFA compared to thermal CA (77 [57, 91] vs. 166 [142, 200] minutes, p < 0.001). Fluoroscopy time was longer with PFA (9.5 [7.6, 12.0] vs. 3.9 [2.9, 6.0] minutes, p < 0.001), with a borderline trend towards higher radiation dose (75 [53, 170] vs. 50 [30, 94] μGy.m2, p = 0.056). Extrapulmonary ablation was frequent (86% and 84% for thermal CA and PFA, p > 0.9). The estimated freedom from the primary endpoint was 79% after PFA and 64% after thermal CA (p = 0.44). The estimated freedom from the secondary endpoint was 76% after PFA and 57% after thermal CA (p = 0.43). LVEF improved by 24% ± 2% (p < 0.001) in patients with the first manifestation of HF and by 14% ± 4% (p = .004) in patients with decompensated HF diagnosed earlier. CONCLUSIONS: Emergent CA of AF during acute HF hospitalization is safe and associated with improved LVEF and good clinical outcomes. In the PFA era, the rate of these procedures is progressively increasing as they are readily available and easy to perform compared to thermal ablation.

2nd Department of Medicine Department of Cardiovascular Medicine Charles University Medical School 1 Prague Czechia

Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czechia

Zobrazit více v PubMed

Hindricks G., Dagres N., Potpara T., et al., “2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration With the European Association for Cardio‐Thoracic Surgery (EACTS),” European Heart Journal 42 (2021): 373–498. PubMed

McDonagh T. A., Metra M., Adamo M., et al., “2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure,” European Heart Journal 42 (2021): 3599–3726. PubMed

Santhanakrishnan R., Wang N., Larson M. G., et al., “Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction,” Circulation 133 (2016): 484–492. PubMed PMC

Fonarow G. C., “ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): Opportunities to Improve Care of Patients Hospitalized With Acute Decompensated Heart Failure,” Reviews in Cardiovascular Medicine 4, no. Suppl 7 (2003): S21–S30. PubMed

Stojadinovic P., Wichterle D., Fukunaga M., et al., “Acute Effect of Atrial Fibrillation on Circulating Natriuretic Peptides: The Influence of Heart Rate, Rhythm Irregularity, and Left Atrial Pressure Overload,” The American Journal of Cardiology 208 (2023): 156–163. PubMed

Packer D. L., Mark D. B., Robb R. A., et al., “Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial,” Journal of the American Medical Association 321 (2019): 1261. PubMed PMC

Marrouche N. F., Brachmann J., Andresen D., et al., “Catheter Ablation for Atrial Fibrillation With Heart Failure,” New England Journal of Medicine 378 (2018): 417–427. PubMed

Di Biase L., Mohanty P., Mohanty S., et al., “Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial,” Circulation 133 (2016): 1637–1644. PubMed

Sohns C., Fox H., Marrouche N. F., et al., “Catheter Ablation in End‐Stage Heart Failure With Atrial Fibrillation,” New England Journal of Medicine 389 (2023): 1380–1389. PubMed

Reddy V. Y., Anic A., Koruth J., et al., “Pulsed Field Ablation in Patients With Persistent Atrial Fibrillation,” Journal of the American College of Cardiology 76 (2020): 1068–1080. PubMed

Reddy V. Y., Dukkipati S. R., Neuzil P., et al., “Pulsed Field Ablation of Paroxysmal Atrial Fibrillation,” JACC: Clinical Electrophysiology 7 (2021): 614–627. PubMed

Reddy V. Y., Gerstenfeld E. P., Natale A., et al., “Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation,” New England Journal of Medicine 389 (2023): 1660–1671. PubMed

Turagam M. K., Neuzil P., Schmidt B., et al., “Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One‐Year Outcomes From the MANIFEST‐PF Registry,” Circulation 148 (2023): 35–46. PubMed

Gorenek B., Halvorsen S., Kudaiberdieva G., et al., “Atrial Fibrillation in Acute Heart Failure: A Position Statement From the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology,” European Heart Journal: Acute Cardiovascular Care 9 (2020): 348–357. PubMed

Hofmann R., Steinwender C., Kammler J., Kypta A., and Leisch F., “Effects of a High Dose Intravenous Bolus Amiodarone in Patients With Atrial Fibrillation and a Rapid Ventricular Rate,” International Journal of Cardiology 110 (2006): 27–32. PubMed

Roy D., Talajic M., Nattel S., et al., “Rhythm Control Versus Rate Control for Atrial Fibrillation and Heart Failure,” New England Journal of Medicine 358 (2008): 2667–2677. PubMed

Wyse D. G., Waldo A. L., DiMarco J. P., et al., “A Comparison of Rate Control and Rhythm Control in Patients With Atrial Fibrillation,” New England Journal of Medicine 347 (2002): 1825–1833. PubMed

Kirchhof P., Camm A. J., Goette A., et al., “Early Rhythm‐Control Therapy in Patients With Atrial Fibrillation,” New England Journal of Medicine 383 (2020): 1305–1316. PubMed

Rillig A., Magnussen C., Ozga A.‐K., et al., “Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure,” Circulation 144 (2021): 845–858. PubMed PMC

Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation,” Journal of the American College of Cardiology 42 (2003): 20–29. PubMed

Mujović N., Dobrev D., Marinković M., Russo V., and Potpara T. S., “The Role of Amiodarone in Contemporary Management of Complex Cardiac Arrhythmias,” Pharmacological Research 151 (2020): 104521. PubMed

Packer D. L., Piccini J. P., Monahan K. H., et al., “Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial,” Circulation 143 (2021): 1377–1390. PubMed PMC

Andrade J. G., Wells G. A., Deyell M. W., et al., “Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation,” New England Journal of Medicine 384 (2021): 305–315. PubMed

Wazni O. M., Dandamudi G., Sood N., et al., “Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation,” New England Journal of Medicine 384 (2021): 316–324. PubMed

Kim D., Yang P.‐S., You S. C., et al., “Treatment Timing and the Effects of Rhythm Control Strategy in Patients With Atrial Fibrillation: Nationwide Cohort Study,” BMJ 373 (2021): n991. PubMed PMC

Chao T.‐F., Chan Y.‐H., Chiang C.‐E., et al., “Early Rhythm Control and the Risks of Ischemic Stroke, Heart Failure, Mortality, and Adverse Events When Performed Early (<3 Months): A Nationwide Cohort Study of Newly Diagnosed Patients With Atrial Fibrillation,” Thrombosis and Haemostasis 122 (2022): 1899–1910. PubMed

Bisbal F., Alarcón F., Ferrero‐De‐Loma‐Osorio A., et al., “Diagnosis‐To‐Ablation Time in Atrial Fibrillation: A Modifiable Factor Relevant to Clinical Outcome,” Journal of Cardiovascular Electrophysiology 30 (2019): 1483–1490. PubMed

Sakamoto K., Tohyama T., Ide T., et al., “Efficacy of Early Catheter Ablation for Atrial Fibrillation After Admission for Heart Failure,” JACC: Clinical Electrophysiology 9 (2023): 1948–1959. PubMed

Turagam M. K., Neuzil P., Schmidt B., et al., “Impact of Left Atrial Posterior Wall Ablation During Pulsed‐Field Ablation for Persistent Atrial Fibrillation,” JACC: Clinical Electrophysiology 10 (2024): 900–912. PubMed

Kueffer T., Tanner H., Madaffari A., et al., “Posterior Wall Ablation By Pulsed‐Field Ablation: Procedural Safety, Efficacy, and Findings on Redo Procedures,” Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society Of Cardiology 26 (2023): euae006. PubMed PMC

Turagam M. K., Neuzil P., Schmidt B., et al., “Safety and Effectiveness of Pulsed Field Ablation for Atrial Fibrillation in Patients With Heart Failure,” JACC: Clinical Electrophysiology 10 (2024): S2405500X24003517. PubMed

Prabhu S., Taylor A. J., Costello B. T., et al., “Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction,” Journal of the American College of Cardiology 70 (2017): 1949–1961. PubMed

Kuck K.‐H., Merkely B., Zahn R., et al., “Catheter Ablation Versus Best Medical Therapy in Patients With Persistent Atrial Fibrillation and Congestive Heart Failure: The Randomized AMICA Trial,” Circulation: Arrhythmia and Electrophysiology 12 (2019): e007731. PubMed

Kistler P. M., Chieng D., Sugumar H., et al., “Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The CAPLA Randomized Clinical Trial,” Journal of the American Medical Association 329 (2023): 127. PubMed PMC

Tzeis S., Gerstenfeld E. P., Kalman J., et al., “2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation,” Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of The Working Groups Oo Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of The European Society Of Cardiology 26 (2024): euae043. PubMed PMC